Hua Medicine’s Pivotal Phase III Monotherapy Trial of Dorzagliatin, a Dual-Acting Glucokinase Modulator, Achieves Primary Efficacy Endpoint in Patients with Type 2 Diabetes

    NEXT STORY
    New Analysis Shows Icosapent Ethyl (Vascepa®) Is Cost Effective and Offers Rare Finding of Better Outcomes at Lower Healthcare Costs When Used to Treat High-Risk Patients with Cardiovascular Disease or Diabetes and Other Risk Factors
    PREV STORY
    Angion Presents Data on the Impact and Burden of Delayed Graft Function at the American Society of Nephrology Kidney Week 2019
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    OPKO Health Enters Companion Animal Health Market

    MIAMI, Oct. 27, 2016 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announced today its ...

    author_avatar
    NASDAQ Market News

    Helix BioPharma Corp. to initiate new L-DOS47 clinical program in pancreatic cancer

    RICHMOND HILL, Ontario, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP), ...

    author_avatar
    NASDAQ Market News

    Report from Extraordinary General Meeting of Immunicum AB (publ) on 8 November 2018

    Press Release 8 November 2018 Report from Extraordinary General Meeting of Immunicum AB (publ) ...

    author_avatar
    NASDAQ Market News